Breast Cancer ASCO 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / breast-cancer-asco-2024-highlights

Following the 2024 ASCO Annual Meeting, Erika P. Hamilton, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent updates in breast cancer.

Erika P. Hamilton, MD, and the Oncology Brothers presenting slides

EP. 1: RxPONDER: Use of AMH Levels in Premenopausal Women

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD
June 17th 2024

Following ASCO 2024, Erika P. Hamilton, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent updates from the RxPONDER trial investigating the use of AMH levels in premenopausal women.

Erika P. Hamilton, MD, and the Oncology Brothers presenting slides

EP. 2: Recent Updates from the postMONARCH Study

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD
June 17th 2024

The Oncology Brothers and Erika P. Hamilton, MD, discuss the postMONARCH study investigating fulvestrant alone vs fulvestrant plus abemaciclib.

Erika P. Hamilton, MD, and the Oncology Brothers presenting slides

EP. 3: INAVO120: Inavolisib Combination Therapy in PIK3CA-Mutated Breast Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD
June 17th 2024

Medical oncologists discuss the INAVO120 study, which is evaluating inavolisib combination therapy in patients with PIK3CA-mutated breast cancer.

Erika P. Hamilton, MD, and the Oncology Brothers presenting slides

EP. 4: Key Updates from DESTINY-Breast06

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD
June 17th 2024

Erika P. Hamilton, MD, and the Oncology Brothers review exciting data from DESTINY-Breast06 and discuss its impact on the evolving treatment landscape.

Erika P. Hamilton, MD, and the Oncology Brothers presenting slides

EP. 5: Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD
June 17th 2024

Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.